# Harmony Biosciences Pre-Announces Record Q2 Revenue of $261M, CFO Departs

> news · REPORTED · 2026-07-16

Harmony Biosciences pre-announced record Q2 2026 net revenue of approximately $261 million for WAKIX, representing 30% year-over-year growth, and reaffirmed full-year 2026 guidance of $1.0 to $1.04 billion. The company simultaneously disclosed that CFO Glenn Reicin stepped down effective July 16, 2026.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company developing and marketing innovative therapies for rare neurological diseases, anchored by WAKIX (pitolisant) for narcolepsy and idiopathic hypersomnia.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716xex99d1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.